港股異動丨中國信達(01359.HK)高開14.62% 擬出資60億元參與重慶螞蟻消費金融增資
格隆匯12月28日丨中國信達(01359.HK)高開14.62%,報1.49港元創近三個半月新高,總市值569億港元。中國信達發佈公吿,2021年12月24日,公司作為增資認購方之一,與重慶螞蟻消費金融有限公司、其他增資認購方及其他現有股東訂立股權認購協議。根據股權認購協議,重慶螞蟻消費金融有限公司向全體增資認購方增發註冊資本人民幣220億元。其中,公司將出資人民幣60億元,以現金方式認購目標公司20%股份權益。增資事項完成後,重慶螞蟻消費金融有限公司的註冊資本將由人民幣80億元增加至人民幣300億元,集團將持有重慶螞蟻消費金融有限公司24.003%股份權益。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.